Aurinia Pharmaceuticals - Common Shares (AUPH) closed at $16.21 on November 11, 2026, down 0.6% from the previous close, on volume of 1,510,605 shares (30-day average 836,175).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Strangle or Risk Reversal | 20-Nov-2616 P : 17 C | 600 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Fri, 30-Oct 8:00 AM ET)
Aurinia’s Patent Settlement with Teva Secures Voclosporin Exclusivity Until 2036
Market Chameleon (Thu, 20-Aug 5:42 AM ET)
Aurinia Settles Patent Litigation with Teva
Business Wire (Wed, 19-Aug 4:05 PM ET)
Tang Capital Boosts Stake in Aurinia Pharmaceuticals—Owns 10% After $3.1 Million Stock Purchase
Market Chameleon (Thu, 4-Jun 7:49 AM ET)
Market Chameleon (Thu, 7-May 5:18 AM ET)
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.
As of November 12, 2026, AUPH stock price climbed to $16.33 with 227,447 million shares trading.
AUPH has a beta of 0.04, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.00 to the broad based SPY ETF.
AUPH has a market cap of $2.19 billion. This is considered a Mid Cap stock.
Last quarter Aurinia Pharmaceuticals - Common Shares reported $84 million in Revenue and $.23 earnings per share. This fell short of revenue expectation by $-627,264 and exceeded earnings estimates by $.01.
In the last 3 years, AUPH traded as high as $19.25 and as low as $4.71.
The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, FESM.
AUPH has underperformed the market in the last year with a price return of +4.1% while the SPY ETF gained +12.5%. However, in the short term, AUPH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.2% vs -1.0% return in SPY. But in the last 2 weeks, AUPH shares have been beat by the market, returning -5.9% compared to an SPY return of -1.5%.
AUPH support price is $15.86 and resistance is $16.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.
